News headlines about Fluidigm (NASDAQ:FLDM) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fluidigm earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 45.1391665677629 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Fluidigm (NASDAQ:FLDM) traded down $0.19 during midday trading on Monday, hitting $6.53. The stock had a trading volume of 168,600 shares, compared to its average volume of 239,525. Fluidigm has a twelve month low of $2.52 and a twelve month high of $8.69. The stock has a market capitalization of $245.41, a P/E ratio of -2.93 and a beta of 3.37. The company has a debt-to-equity ratio of 5.00, a quick ratio of 2.46 and a current ratio of 3.02.

Separately, ValuEngine downgraded Fluidigm from a “sell” rating to a “strong sell” rating in a report on Thursday, November 9th.

In related news, insider Levin Capital Strategies, L.P. bought 95,843 shares of Fluidigm stock in a transaction dated Tuesday, October 10th. The stock was acquired at an average cost of $4.57 per share, with a total value of $438,002.51. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders have bought 498,335 shares of company stock valued at $2,480,132. 4.70% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at

About Fluidigm

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Insider Buying and Selling by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Stock Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related stocks with our FREE daily email newsletter.